Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratympanic methylprednisolone for serous otitis versus standard treatment
IRCT20240108060650N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of methylprednisolone and fluticasone in non-suppurative otitis media (OME) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Hearing status improvement, Tympanogram status improvement and 1 more. Started Oct 2023; status: completed.
02
Drugs
methylprednisolonefluticasone
03
Conditions
non-suppurative otitis media (OME)
Beyond the preview
Go deeper on IRCT20240108060650N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240108060650N1.